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Acidosis is associated with poor outcome in critical
illness. However, acidosis - both hypercapnic and
metabolic - has direct effects that can limit tissue injury
induced by many causes. There is also a clear potential
for off-target harm with acute exposure (for example,
raised intracranial pressure, pulmonary hypertension),
and with exposure for prolonged periods (for example,
increased risk of infection) or at high doses. Ongoing
comprehensive determination of molecular, cellular
and physiologic impact across a range of representative
pathologies will allow us to understand better the
risks and benefits of hypercapnia and acidosis during
critical illness.cardiac contractility, but that cardiac output was main-The effects of acidosis in critical illness are complex and
depend on multiple factors, including the etiology of the
acidosis (hypercapnic versus metabolic), the degree of
acidosis and whether the acidosis accumulates acutely or
more gradually, where compensatory or adaptive mecha-
nisms may blunt its effects. While acidosis is tradition-
ally associated with poor outcome in critical illness, it is
not clear to what extent - if any - this is a causal rela-
tionship. In any case, simple avoidance of acidosis is
generally not feasible in the critically ill. In fact, conven-
tional protective ventilation strategies that minimize
lung stretch increase the prevalence of hypercapnic acid-
osis (HCA) in the critically ill, and have been clearly
demonstrated to save lives in patients with acute respira-
tory distress syndrome. However, there is also a clear po-
tential for harm with HCA or metabolic acidosis (MAC),* Correspondence: curleyg@smh.ca
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medium, for 12 months following its publicat
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reproduction in any medium, provided the orwhether due to acute exposure (for example, raised
intracranial pressure, pulmonary hypertension), exposure
for prolonged periods of time (for example, increased
risk of infection) or high concentrations. These com-
plexities are further underlined by the findings in mul-
tiple preclinical studies that acidosis may have direct
effects which can protect cells and organs in the setting
of acute organ injury. Thus, managing acidosis is an in-
tegral component of critical care, and efforts to deepen
our understanding of its consequences are therefore
welcome.
Stengl and colleagues report a study into the effects of
relatively severe (pH 7.1) HCA and MAC on the cardio-
vascular system and distal organ perfusion in the healthy
pig [1]. They found that acute HCA or MAC reduced
tained as a result of increased heart rate and, in the case
of HCA, reduced systemic vascular resistance. They ex-
amined regional perfusion, and found that HCA - but
not MAC - increased portal and carotid arterial flow,
while neither HCA nor MAC affected renal blood flow.
Finally, they examined right ventricular trabeculae from
these animals to evaluate contractile force generation
during normal pH and acidosis. Their study raises a
number of key issues with regard to the hemodynamic
effects of acidosis that deserve further consideration.
The effects of hypercapnia and acidosis on pulmonary
hemodynamics are important, given the prevalence of
pulmonary arterial hypertension in acute respiratory dis-
tress syndrome and other critical illnesses [2]. HCA and
MAC increased pulmonary artery pressures to a com-
parable extent, with MAC primarily increasing pulmon-
ary vascular resistance while HCA increased both
cardiac output and pulmonary vascular resistance [1]. El-
evated pulmonary vascular pressure has the potential to
increase right heart strain and worsen clinical outcomes.
However, the fact that HCA increased cardiac output
despite raising pulmonary vascular resistance suggests
that right ventricular function was preserved or evenntral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the effects of HCA on pulmonary hemodynamics may
be less significant in pre-existing pulmonary hypertension
[3]. Hypercapnia is a less potent pulmonary vasoconstrictor
than hypoxia, and its physiologic role may be in augment-
ing hypoxic vasoconstriction [4], enhancing matching of
pulmonary perfusion to ventilation and thereby increasing
arterial oxygen partial pressure [5,6]. Finally, HCA may
actually attenuate the development of hypoxia-induced
pulmonary hypertension by reducing oxidant stress [7].
The contrasting effects of HCA and MAC in the sys-
temic circulation are of interest. While both HCA and
MAC have a direct negative inotropic effect, the indirect
hypercapnia-mediated sympatho-adrenal effects of an in-
creased heart rate and a decreased afterload lead to a
net increase in cardiac output [1]. As the authors note,
cardiac output could be impaired in patients for whom
sympatho-adrenal mediated increases in heart rate are
not achievable. However, it is somewhat reassuring to
note that HCA can increase tissue oxygen delivery through
other mechanisms. As discussed, HCA increases arterial
oxygen tension by improving ventilation/perfusion ratio
(V/Q) matching [4,8]. HCA also shifts the oxyhemoglobin
dissociation curve rightwards (that is, the Bohr effect),
thereby increasing tissue oxygen availability [9]. HCA may
acutely elevate hematocrit by a mechanism that might
involve sympathetically mediated auto-transfusion [10],
further increasing tissue oxygen delivery. Acidosis may
also reduce cellular respiration and oxygen consumption
[11], which may further benefit a supply/demand imbal-
ance. In addition, HCA increases oxygen tension in both
subcutaneous tissues and in the intestinal wall [12]. None-
theless, the findings of this study suggest that the judicious
use of HCA in patients with maximally activated adrener-
gic systems (heart failure or sepsis) is advised.
The differential effects of HCA on systemic organ
blood flow in this study (increased portal venous blood
flow, unchanged renal blood flow) emphasizes the need
for integrative studies of this kind to clearly outline the
risks and benefits of HCA, particularly off-target effects.
A structured approach should incorporate ongoing com-
prehensive determination of molecular, cellular and tis-
sue impact across a range of representative pathologies.
These findings provide important additional insights into
the hemodynamics of MAC and HCA. More broadly, they
reinforce the concept that acidosis - whether metabolic or
hypercapnic - exerts potent physiologic effects, and these
effects may result in benefit or harm, particularly in the
critically ill. We need to think about the use of hypercapnia
just as we would any therapy. Consider in this regard
the immunologic effects of HCA, whereby its potent
immunosuppressive effects decrease lung injury in pre-
clinical studies of ventilation-induced lung injury, is-
chemia–reperfusion injury, and early pneumonia andsystemic sepsis [13,14]. However, as with any pharma-
cologic agent, dose and timing are important. The bene-
fits of short-term application of HCA may be offset when
the altered carbon dioxide state is allowed to persist. This
may be particularly true where an intact host immune
response is central to effective bacterial clearance. In
this regard, the finding that HCA worsens prolonged
untreated pneumonia [15] can be predicted from know-
ledge of its mechanisms of action. The importance of
dose is evidenced by the finding that carbon dioxide
partial pressure levels of 120 mmHg cause mitochondrial
dysfunction [16]. Even permissive hypercapnia must have
safe and rational upper limits.
In summary, acidosis remains prevalent in the critic-
ally ill, and advances in our understanding of the effects
of acidosis help us to rationally balance the risks and
benefits of acidosis in our patients. Our research efforts
should focus on fully understanding the potential mech-
anisms by which hypercapnia and acidosis contribute to
the pathogenesis of organ injury and disease. Such insights
should advance our understanding of the situations in
which hypercapnia may be helpful or dangerous, and
should guide clinicians in regard to the rational manage-
ment of carbon dioxide tension in diverse disease states.
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